Peptide antitumor vaccines targeting HER2/neu
Open Access
- 10 December 2022
- journal article
- review article
- Published by Publishing House ABV Press in Russian Journal of Biotherapy
- Vol. 21 (4) , 22-29
Abstract
Antitumor vaccines are aimed at correcting cellular immunity by overcoming immunological tolerance with eluding surveillance due to the specific presentation of tumor-associated or tumor-specific antigens to immunocompetent cells.The purpose of this review was to study modern strategies for the development of antitumor vaccines containing epitopes of HER2/neu receptors acting as tumor-associated antigens. Approaches to the creation of such vaccines are classified by targeting the T-cell link or B-cells by the choice and length of the epitopes used or by the use of specific adjuvants.The review provides information on this topic, obtained from more than 50 publications of the last 20 years, found in the most significant sources of citation. The text is categorized for the convenience of perception by scientists of different specialties and is completed with a brief conclusion with an emphasis on development prospects. The results of clinical studies of vaccines with an analysis of the immunological features of the results of immunotherapy, mainly breast cancer with HER2/neu expression, are considered. Vaccines targeting different histocompatibility complexes are compared. The review traces the evolution of vaccine preparations from the simplest containing short peptide sequences to complex combined systems, including viral vectors. Attention is paid to various methodological approaches used in the development of such drugs: from computer design and phage display in experiments in vitro/in vivo. The emphasis is placed on the problem of a personalized approach to vaccination of an oncological patient associated with a mutation process occurring inside tumors and leading to the appearance of unique tumor-associated antigens. The participation of complement system components in antibody-mediated lysis of tumor cells induced by the presented vaccines is discussed.Thus, the review introduces readers to the existing directions of creating immune drugs designed to suppress the development of the tumor process by activating the body’s own immune forces and the prospect of their development.Keywords
This publication has 52 references indexed in Scilit:
- Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastomaCancer Immunology, Immunotherapy, 2012
- Challenges in Immunotherapy Presented by the Glioblastoma Multiforme MicroenvironmentJournal of Immunology Research, 2011
- Clinical trial results of the HER‐2/neu (E75) vaccine to prevent breast cancer recurrence in high‐risk patientsCancer, 2011
- Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiformeNeuro-Oncology, 2011
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- Anti-HER2 vaccines: new prospects for breast cancer therapyCancer Immunology, Immunotherapy, 2010
- Concurrent Trastuzumab and HER2/neu-Specific Vaccination in Patients With Metastatic Breast CancerJournal of Clinical Oncology, 2009
- A gene expression profile for detection of sufficient tumour cells in breast tumour tissue: microarray diagnosis eligibilityBMC Medical Genomics, 2009
- Transforming growth factor-β signaling: emerging stem cell target in metastatic breast cancer?Breast Cancer Research and Treatment, 2008
- Sustained antigen presentation can promote an immunogenic T cell response, like dendritic cell activationProceedings of the National Academy of Sciences, 2007